History
  • No items yet
midpage
Merck & Cie v. Watson Laboratories, Inc.
822 F.3d 1347
Fed. Cir.
2016
Read the full case

Background

  • The sole asserted claim (claim 4) of U.S. Patent No. 6,441,168 covers a crystalline calcium salt form of 5‑methyltetrahydrofolic acid (MTHF); application filed Apr 17, 2000 (critical date Apr 17, 1999).
  • In 1997–1998 Merck and Weider discussed a joint venture to market MTHF; they executed a Confidentiality Agreement in Feb 1998 containing §5.2 requiring any "definitive agreement" to be signed by both parties.
  • Weider declined the joint venture in Aug 1998 but asked to buy 2 kg of MTHF. On Sept 9, 1998 Merck manager Roland Martin faxed Weider price ($25,000/kg), payment (60 days net), delivery (free to Utah facility), and invited Weider to send an order to him.
  • Weider responded Sept 16 that it would order 2 kg and requested spec sheets and insurance; Merck provided specs Sept 25 and confirmed a "first order" Oct 8, 1998, but no delivery was ever made and the order was later canceled.
  • District Court found MTHF was ready for patenting by Sept 1998 but held Martin’s fax was not a commercial offer because it lacked certain safety/liability terms and the Confidentiality Agreement required signed definitive agreements.
  • The Federal Circuit reversed, holding Martin’s Sept 9 fax constituted a commercial offer for sale that triggered the pre‑AIA §102(b) on‑sale bar, invalidating claim 4.

Issues

Issue Plaintiff's Argument (Merck) Defendant's Argument (Watson) Held
Whether a commercial offer for sale occurred before the critical date Martin’s fax was not a binding offer because it lacked safety/liability terms and §5.2 of the Confidentiality Agreement required signed definitive agreements The fax contained definite price, quantity, delivery, and payment terms in response to Weider’s request and thus was an offer The fax was a commercial offer for sale triggering the on‑sale bar
Whether later testimony can overcome contemporaneous documents Merck relied on expert testimony that industry standard safety/apportionment terms were missing and thus no offer Watson relied on documentary record (fax, emails, specs, confirmation) showing both parties treated communication as an offer Court gave priority to contemporaneous documentary evidence over post hoc testimony; testimony insufficient to negate the offer
Effect of Confidentiality Agreement §5.2 on formation of an offer §5.2 made any transaction nonbinding until a signed definitive agreement existed, so the fax could not be an offer The Confidentiality Agreement governed joint venture talks, did not require that offers be signed to be valid, and did not prevent a separate stand‑alone sales offer §5.2 did not prevent the fax from being a commercial offer; offers and signed contracts need not be in same document
Whether failure to consummate a sale defeats the on‑sale bar Merck suggested that lack of delivery and later cancellation meant no commercial exploitation Watson argued an offer alone is sufficient to trigger the on‑sale bar even if sale not completed The on‑sale bar is triggered by a commercial offer irrespective of whether the sale was completed

Key Cases Cited

  • Pfaff v. Wells Elecs., Inc., 525 U.S. 55 (defines "ready for patenting" and on‑sale bar elements)
  • Group One, Ltd. v. Hallmark Cards, Inc., 254 F.3d 1041 (contract‑law standard for what constitutes an offer for sale)
  • Cargill, Inc. v. Canbra Foods, Ltd., 476 F.3d 1359 (price, quantity, and delivery terms can constitute invalidating offer)
  • Linear Tech. Corp. v. Micrel, Inc., 275 F.3d 1040 (objective expressed intent controls offer analysis)
  • Scaltech, Inc. v. Retec/Tetra, LLC, 269 F.3d 1321 (critical date and on‑sale bar principles)
  • Robotic Vision Sys., Inc. v. View Eng’g, Inc., 249 F.3d 1307 (invalidity under on‑sale bar is legal question based on facts)
  • Lacks Indus., Inc. v. McKechnie Vehicle Components USA, Inc., 322 F.3d 1335 (insufficient conclusory testimony about industry practice cannot defeat documentary evidence)
  • Hamilton Beach Brands, Inc. v. Sunbeam Prods., Inc., 726 F.3d 1370 (on‑sale bar applies to offers even if sale not executed)
  • Atlanta Attachment Co. v. Leggett & Platt, Inc., 516 F.3d 1361 (on‑sale bar purpose and precedent)
  • City of Elizabeth v. American Nicholson Pavement Co., 97 U.S. 126 (historical basis for denying patents after public commercialization)
  • Bonito Boats, Inc. v. Thunder Craft Boats, Inc., 489 U.S. 141 (public sale of unpatented article bars patent protection)
  • Abbott Labs. v. Geneva Pharm., Inc., 182 F.3d 1315 (on‑sale bar as a policy to prevent withdrawing inventions from public domain)
  • In re Giannelli, 739 F.3d 1375 (application of pre‑AIA §102(b) timing)
Read the full case

Case Details

Case Name: Merck & Cie v. Watson Laboratories, Inc.
Court Name: Court of Appeals for the Federal Circuit
Date Published: May 13, 2016
Citation: 822 F.3d 1347
Docket Number: 2015-2063, 2015-2064
Court Abbreviation: Fed. Cir.